The FDA Orange Book Explained: Drug Patent and Exclusivity Database
Published April 6, 2026
The FDA Orange Book is the official U.S. government database of every approved drug, its patents, and its exclusivity periods. Formally titled "Approved Drug Products with Therapeutic Equivalence Evaluations," it is the single most important reference for understanding when generic competition can legally enter the market. Anyone tracking drug patent cliffs, generic timelines, or pharmaceutical competition starts here.
What the Orange Book Contains
For every approved drug, the Orange Book provides a structured record of the legal and regulatory protections that keep generics off the market. Each listing includes:
- Active ingredient — the chemical compound (e.g., atorvastatin calcium)
- Dosage form and route — tablet, capsule, injection, etc.
- Proprietary name — the brand name (e.g., Lipitor)
- Applicant — the company that holds the approved NDA
- Patent numbers — every patent the applicant has listed, with expiration dates
- Exclusivity codes — FDA-granted marketing exclusivity periods (see table below)
- Therapeutic equivalence rating — AB, BX, etc., indicating whether generics are substitutable
Key Exclusivity Codes
Exclusivity is separate from patent protection. Even after a patent expires, regulatory exclusivity can block generic approval. These are the most common codes you will encounter:
| Code | Type | Duration | What It Protects |
|---|---|---|---|
| NCE | New Chemical Entity | 5 years | First-ever approval of a new active ingredient. No ANDA can even be filed during this period. |
| ODE | Orphan Drug | 7 years | Drugs for rare diseases (fewer than 200,000 patients). Blocks approval of the same drug for the same indication. |
| NP | New Patient Population | 3 years | New clinical studies for a new indication, dosage form, or route of administration. |
| PED | Pediatric | 6 months | Added to existing patents/exclusivity when manufacturer completes FDA-requested pediatric studies. |
| ORP | Orphan Drug (Rare Pediatric) | 7 years | Orphan drug designation specifically for rare pediatric diseases. |
| QICE | Qualified Infectious Disease | 5 years + limelight | GAIN Act exclusivity for antibiotics targeting serious infections. |
A single drug can carry multiple exclusivity codes simultaneously. For example, a new antibiotic for a rare disease could have both NCE (5 years) and ODE (7 years) exclusivity, with the longer one controlling generic entry.
How to Use the Electronic Orange Book
The electronic Orange Book is available at electronic.orangebook.fda.gov. You can search by:
- Active ingredient — find all approved products containing a specific compound
- Proprietary name — look up a brand name directly
- Application number — find a specific NDA or ANDA
- Patent number — see which drugs are protected by a particular patent
For each result, the patent and exclusivity tab shows every listed patent with its expiration date. This is the data that generic manufacturers review when evaluating whether to file a Paragraph IV certification challenging the brand's patents.
What Is NOT in the Orange Book
The Orange Book has important limitations. It does not include:
- Biologic products — monoclonal antibodies, vaccines, and cell therapies are listed in the Purple Book instead. This includes blockbuster drugs like Humira (adalimumab) and Keytruda (pembrolizumab).
- Over-the-counter (OTC) drugs — unless they were originally approved under an NDA
- Manufacturing process patents — the Orange Book only lists patents covering the drug compound, formulation, or method of use, not how it is manufactured
- Patent validity assessments — the FDA lists patents as submitted by the NDA holder without evaluating whether they are valid or enforceable
Orange Book vs. Purple Book
The distinction matters for tracking patent cliffs. Small-molecule drugs (like Lipitor, Nexium, or Eliquis) are in the Orange Book. Biologic drugs (like Humira, Stelara, or Keytruda) are in the Purple Book. As the pharmaceutical industry shifts toward biologics, an increasing share of major patent expirations involve drugs covered by the Purple Book rather than the Orange Book. For more on how biologic competition differs, see our guide to biosimilars vs. generics.
Frequently Asked Questions
What is the FDA Orange Book?
The FDA Orange Book — officially titled "Approved Drug Products with Therapeutic Equivalence Evaluations" — is the FDA's comprehensive database of all approved prescription drugs in the United States. For each drug, it lists the associated patents, patent expiration dates, regulatory exclusivity periods, and therapeutic equivalence ratings. It is the definitive reference for determining when generic competition can legally enter the market.
Is the Orange Book free to access?
Yes, the FDA Orange Book is free and publicly available online at electronic.orangebook.fda.gov. The electronic version is updated daily and includes a search interface where you can look up drugs by active ingredient, proprietary name, applicant, or application number. A downloadable data file is also available for bulk analysis.
What is the difference between the Orange Book and Purple Book?
The Orange Book covers drugs approved under New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) — primarily small-molecule drugs. The Purple Book covers biological products approved under Biologics License Applications (BLAs), including monoclonal antibodies, vaccines, and cell therapies. If a product is a biologic, its patents and biosimilar information are in the Purple Book, not the Orange Book.
How often is the Orange Book updated?
The electronic Orange Book at electronic.orangebook.fda.gov is updated daily. The print edition, which was published annually in a physical book with an orange cover (hence the name), was discontinued after the 2014 edition. For the most current information on patents and exclusivity, always use the electronic version.
About This Data
Drug patent and exclusivity data from the FDA Orange Book and USPTO PatentsView API. See our methodology.